For hundreds of millions of people living with diabetes worldwide, multiple daily insulin injections are a life‑sustaining routine. Insulin pen needles - tiny devices only a few millimetres long and as thin as a hair - directly impact dosage accuracy, injection‑related pain, and treatment adherence. This highly specialised niche market stands as a prime example of perfect integration between materials science, precision manufacturing and human‑centred design.

Extreme Specifications: Pursuit from Millimetres to Micrometres

The core design goals of insulin pen needles are minimal invasiveness and pain‑free injection. To achieve this, the industry continuously pursues shorter lengths and finer diameters. Today, mainstream needle lengths have been reduced from early 8 mm and 6 mm to 4 mm, 5 mm, and even 3 mm. Shorter needles ensure accurate delivery of insulin into subcutaneous tissue rather than muscle layers, lowering pain and risks of blood glucose fluctuations. In terms of diameter, gauges have evolved from early 31G (0.25 mm) and 32G (0.23 mm) to ultra‑fine 33G (0.20 mm) and even finer 34G models. For instance, Beipu Medical's "Hummingbird Needle" is renowned for its ultra‑fine dimensions and specialised tip‑processing technology.

Precision Design of Materials and Structure

Insulin pen needles generally consist of a medical‑grade stainless‑steel cannula, plastic hub and protective cap. The cannula represents the technical core:

Ultra‑thin‑wall technology: While maintaining structural strength, the cannula wall is made as thin as possible to enlarge the inner lumen. This enables insulin solution to flow through with lower resistance and higher velocity, and reduces clogging risks caused by drug crystallisation.

Needle‑tip geometry: Needle tips are commonly ground into multi‑facet bevels with no fewer than three cutting surfaces, forming an acute angle of 18° or smaller. This design significantly lowers the penetration force required for skin puncture (typically below 0.7 N), delivering a sharp yet smooth insertion sensation.

Surface coating: The outer cannula surface is universally coated with silicone oil (e.g. Superstick dual‑layer silicone adhesion technology) for lubrication, further minimising friction during penetration.

Rigorous Challenges in Manufacturing Processes

Producing such micro‑sized, high‑precision needles involves extremely complex procedures. Take the world's finest insulin pen needle (0.18 mm in diameter, 3 mm in length) as an example: its production demands micrometre‑level precision machining. First, sheets of specific‑grade stainless steel (such as 304 or 316LVM) undergo nearly ten stamping steps to be rolled into ultra‑fine seamless tube blanks comparable in size to mosquito mouthparts. Subsequent multiple cold‑drawing and heat‑treatment processes shape the blanks into target dimensions while adjusting material hardness and toughness. Tip grinding is a critical step, performed via high‑speed rotating grinding wheels with ultra‑precision multi‑facet polishing. Finally, multiple post‑processing steps follow, including electropolishing for burr removal, silicone coating, cleaning and sterilisation. The entire production takes place in Class‑10,000 or higher cleanroom environments, supported by strict 100‑percent and sampling inspections covering dimensional measurement, penetration‑force testing, flow‑rate testing and biocompatibility evaluation.

Patient Experience and Market Trends

Advancements in insulin pen needles have directly improved patient treatment experience. Finer and shorter needles offer nearly pain‑free injection, easing patients' fear and psychological burden and enhancing long‑term treatment adherence. Additionally, fixed‑dose pen needles with easier operation or self‑destructive needles with safety shields are available for children, patients with poor eyesight or limited hand dexterity.

The market is dominated by global giants including Novo Nordisk, BD, Terumo and Nipro. Meanwhile, Chinese manufacturers represented by Beipu Medical, Ningbo Meisheng and Suzhou Shali are rapidly rising through technological innovation and cost advantages. In the future, insulin pen needles will continue evolving toward intelligence (connected to smart pens to record injection data), personalisation (customised lengths based on patients' subcutaneous fat thickness) and integrated care (incorporating alcohol pads), becoming an indispensable component of refined diabetes management.